Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B

Table 4 Treatment response, mycological response, and crude mortality rates

Outcome	Micafungin		Liposomal amphotericin B		P value^a		Total
	Non-ICU (n = 127)	ICU (n = 120)	Non-ICU (n = 136)	ICU (n = 110)	Non-ICU	ICU	Non-ICU (n = 263)	ICU (n = 230)	P value
Overall treatment success	108 (85.0)	75 (62.5)	98 (72.1)	73 (66.4)	0.0113*	0.5828	206 (78.3)	148 (64.3)	0.0006*
Mycological response	109 (85.8)	88 (73.3)	106 (77.9)	79 (71.8)	0.1115	0.8825	215 (81.7)	167 (72.6)	0.2371
All-cause mortality at day 8	6 (4.7)	25 (20.8)	14 (10.3)	18 (16.4)	0.1057	0.4028	20 (7.6)	43 (18.7)	0.8935
All-cause mortality at day 30	25 (19.7)	46 (38.3)	32 (23.5)	38 (34.5)	0.4589	0.5852	57 (21.7)	84 (36.5)	0.0003*

Data presented as n (%). ICU, intensive care unit. ^aMicafungin versus liposomal amphotericin B. *Statistically significant.

ISSN: 1364-8535